Related references
Note: Only part of the references are listed.mTOR inhibitor-associated dermatologic and mucosal problems
Josep M. Campistol et al.
CLINICAL TRANSPLANTATION (2010)
Comprehensive lung injury pathology induced by mTOR inhibitors
Guadalupe Aparicio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Christine M. Hartford et al.
CLINICAL CANCER RESEARCH (2009)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Phase I study of everolimus in pediatric patients with refractory solid tumors
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus
P. Chuang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
Hypophosphatemia: An update on its etiology and treatment
A Gaasbeek et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy
E Mahé et al.
TRANSPLANTATION (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
Share Paper
